Flare Therapeutics Presents FX-909 Phase 1 Dose Escalation and Expansion Clinical Trial Design at the 2024 ASCO Genitourinary Cancers Symposium
--First-in-human trial evaluating safety, tolerability, and clinical activity of FX-909 in patients with advanced solid malignancies including advanced urothelial carcinoma-- CAMBRIDGE, Mass., Jan. 26, 2024 /PRNewswire/ -- Flare Therapeutics Inc., a biotechnology company targeting...
--First-in-human trial evaluating safety, tolerability, and clinical activity of FX-909 in patients with advanced solid malignancies including advanced urothelial carcinoma-- CAMBRIDGE, Mass., Jan. 26, 2024 /PRNewswire/ -- Flare Therapeutics Inc., a biotechnology company targeting...
